Industry
Biotechnology
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Loading...
Open
0.90
Mkt cap
44M
Volume
450K
High
0.91
P/E Ratio
-0.45
52-wk high
6.80
Low
0.80
Div yield
N/A
52-wk low
0.80
Portfolio Pulse from
November 11, 2024 | 3:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 11:37 am
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 11:28 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 2:14 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
September 13, 2024 | 2:03 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:31 am
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 10:36 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.